<DOC>
	<DOCNO>NCT01154426</DOCNO>
	<brief_summary>This phase I trial study side effect best dose give ABT-888 together gemcitabine hydrochloride treat patient advance solid tumor . ABT-888 may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , gemcitabine hydrochloride , work different way stop growth tumor cell , either kill cell stop divide . Giving ABT-888 together gemcitabine hydrochloride may kill tumor cell .</brief_summary>
	<brief_title>ABT-888 Gemcitabine Hydrochloride Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Establish maximum-tolerated dose ( MTD ) dose-limiting toxicity ( DLTs ) combination ABT-888 gemcitabine ( gemcitabine hydrochloride ) patient advance solid tumor . SECONDARY OBJECTIVES : I . Establish safety tolerability combination ABT-888 gemcitabine patient solid tumor . II . Determine effect ABT-888 gemcitabine treatment DNA damage response analysis marker Ataxia telangiectasia mutate ( ATM ) peripheral blood mononuclear cell ( PBMCs ) . III . Determine pharmacokinetics ABT-888 gemcitabine administer combination . IV . Determine generation gemcitabine triphosphate PBMCs . V. Document evidence antitumor response . OUTLINE : This dose-escalation study . Patients receive oral ABT-888 twice daily day 1-14 gemcitabine hydrochloride IV 30 minute day 1 , 8 , 15 . Courses repeat every 21* day absence disease progression unacceptable toxicity . After completion study therapy , patient follow least 4 week . NOTE : *Patients previously enrol 4-week schedule ( ABT-888 twice daily day 1-21 gemcitabine IV 30 minute weekly day 1 , 8 , 15 , course repeat every 28 day ) continue 4-week schedule .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<criteria>Histologically confirm solid tumor meet 1 follow criterion : Progressive disease follow standard therapy Disease acceptable standard treatment option exist May receive 02 prior chemotherapeutic regimen ( singleagent combination chemotherapy ) Willing undergo BRCA mutation analysis Known BRCA mutation allow All patient , dose level , without know BRCA mutation undergo screen BRCAPRO program ass likelihood BRCA mutation Patients BRCAPRO likelihood gene mutation ≥ 20 % must undergo BRCA gene test Myriad Genetic Laboratories order participate study Patients eligible whether know deleterious BRCA 1 2 mutation mutation uncertain significance No CNS disease ( e.g. , brain metastasis glioma ) No active seizure history seizure disorder ECOG performance status 02 ( Karnofsky 60100 % ) Life expectancy &gt; 3 month ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin &lt; 2.0 mg/dL AST ALT &lt; 3 time upper limit normal Creatinine normal OR creatinine clearance &gt; 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able swallow pill HIVpositive patient allow provided CD4 count &lt; 500 protease inhibitor No uncontrolled diarrhea No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would limit compliance study requirement No concurrent anticancer therapy agents More 4 week since prior major surgery , radiotherapy , chemotherapy ( 6 week mitomycin C nitrosoureas ) recover Prior gemcitabine hydrochloride PARP inhibition therapy , include ABT888 , allow No prior combination gemcitabine hydrochloride PARP inhibitor Concurrent bisphosphonate IV allow provide treatment initiate study therapy ( patient bone metastasis hypercalcemia ) Patients prostate cancer must continue luteinizinghormone releasinghormone agonist therapy discontinue antiandrogens ( ≥ 6 week since bicalutamide ≥ 4 week since flutamide ) No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>